Bookrunners Credit Suisse and Robert W. Baird to assist with offering
By Devika Patel
Knoxville, Tenn., June 10 – Sarepta Therapeutics, Inc. said it priced a $37.5 million public sale of stock. The deal was announced Wednesday.
The company will sell 2,102,000 common shares at $17.84 per share. The price per share is a 15.01% discount to the June 9 closing share price of $20.99.
Credit Suisse Securities (USA) LLC and Robert W. Baird & Co. are the bookrunners.
Settlement is expected June 14.
Proceeds will be used for product and commercial development, manufacturing, business development activities and other general corporate purposes.
Sarepta is a Cambridge, Mass.-based biopharmaceutical company.
| Issuer: | Sarepta Therapeutics, Inc.
|
| Issue: | Common stock
|
| Amount: | $37.5 million
|
| Shares: | 2,102,000
|
| Price: | $17.84
|
| Warrants: | No
|
| Bookrunners: | Credit Suisse Securities (USA) LLC and Robert W. Baird & Co.
|
| Announcement date: | June 8
|
| Pricing date: | June 10
|
| Settlement date: | June 14
|
| Stock symbol: | Nasdaq: SRPT
|
| Stock price: | $20.99 at close June 9
|
| Market capitalization: | $913.06 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
